Cardiac effects of drug therapy for non-small cell lung cancer with EGFR gene mutation
Non-small cell lung cancer(NSCLC)accounts for about 85％of lung cancer patients,and the incidence is increasing year by year,while the rapid development of molecular targeted therapy has brought hope to patients with advanced non-small cell lung cancer.Among them,epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI)in the treatment of non-small cell lung cancer will inevitably appear different degrees of cardiovascular toxicity.It is necessary to pay attention to the cardiovascular toxicity caused by EGFR-TKI in the treatment of non-small cell lung cancer.This paper analyzes the cardiovascular toxicity caused by EGFR-TKI in the treatment of advanced non-small cell lung cancer,and explores the important clinical studies based on immunotherapy inhibitors in the treatment of EGFR-TKI resistant NSCLC patients,so as to provide references for better cure of non-small cell lung cancer and prevention and treatment of related complications.
NETL
NSTL
万方数据
